STOCK TITAN

Disc Medicine (NASDAQ: IRON) CLO exercises options, sells 2,500 common shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Disc Medicine, Inc. Chief Legal Officer Rahul Khara exercised stock options and sold common shares in a pre-planned set of transactions. He exercised options for 2,500 shares of common stock at $14.69 per share and sold 2,500 shares at $75.00 per share. After these trades, he directly holds 52,173 common shares. The transactions were executed under a Rule 10b5-1 trading plan adopted on March 19, 2026, indicating they were pre-arranged rather than timed discretionarily.

Positive

  • None.

Negative

  • None.
Insider Khara Rahul
Role Chief Legal Officer
Sold 2,500 shs ($188K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 1,649 $0.00 --
Exercise Common Stock 1,649 $14.69 $24K
Sale Common Stock 1,649 $75.00 $124K
Exercise Stock Option (Right to Buy) 851 $0.00 --
Exercise Common Stock 851 $14.69 $13K
Sale Common Stock 851 $75.00 $64K
Holdings After Transaction: Stock Option (Right to Buy) — 54,804 shares (Direct, null); Common Stock — 53,822 shares (Direct, null)
Footnotes (1)
  1. The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026. The shares underlying this option are fully vested and exercisable as of the date hereof.
Shares sold 2,500 shares Total common stock sold in open-market transactions
Sale price $75.00 per share Price for common stock sales on June 26 and June 29, 2026
Options exercised 2,500 shares Common shares acquired via stock option exercises
Option exercise price $14.69 per share Exercise price of stock options converted into common stock
Shares held after transactions 52,173 shares Direct common stock ownership after reported trades
10b5-1 plan adoption date March 19, 2026 Date Rahal Khara’s trading plan was adopted
Option expiration February 7, 2032 Expiration date of the exercised stock options
Rule 10b5-1 trading plan regulatory
"The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy) financial
"security_title: "Stock Option (Right to Buy)""
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
open-market sale financial
"transaction_action: "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Common Stock financial
"security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Khara Rahul

(Last)(First)(Middle)
C/O DISC MEDICINE, INC.
321 ARSENAL STREET, SUITE 101

(Street)
WATERTOWN MASSACHUSETTS 02472

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Disc Medicine, Inc. [ IRON ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Legal Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/26/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/26/2026M(1)851A$14.6953,024D
Common Stock06/26/2026S(1)851D$7552,173D
Common Stock06/29/2026M(1)1,649A$14.6953,822D
Common Stock06/29/2026S(1)1,649D$7552,173D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$14.6906/26/2026M(1)851 (2)02/07/2032Common Stock851$056,453D
Stock Option (Right to Buy)$14.6906/29/2026M(1)1,649 (2)02/07/2032Common Stock1,649$054,804D
Explanation of Responses:
1. The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on March 19, 2026.
2. The shares underlying this option are fully vested and exercisable as of the date hereof.
By: /s/ Rahul Khara06/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Disc Medicine (IRON) report for Rahul Khara?

Disc Medicine reported that Chief Legal Officer Rahul Khara exercised options for 2,500 common shares and sold 2,500 shares. These trades occurred as part of a planned program and reflect both an option exercise and a matching open-market sale.

At what prices did Rahul Khara trade Disc Medicine (IRON) stock?

Rahul Khara exercised stock options at an exercise price of $14.69 per share and sold 2,500 common shares at $75.00 per share. This shows a significant spread between the option strike price and the market sale price.

How many Disc Medicine (IRON) shares does Rahul Khara hold after these trades?

Following the reported transactions, Rahul Khara directly holds 52,173 shares of Disc Medicine common stock. This remaining stake indicates he continues to maintain a meaningful equity position after the option exercise and related open-market sales.

Were Rahul Khara’s Disc Medicine (IRON) stock sales under a 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on March 19, 2026. Such plans pre-schedule trades, suggesting these sales were part of a structured program rather than opportunistic market timing.

What type of securities did Rahul Khara exercise and sell at Disc Medicine (IRON)?

Rahul Khara exercised stock options described as a “Stock Option (Right to Buy)” to acquire 2,500 shares of common stock. He then sold 2,500 shares of that common stock in open-market transactions at $75.00 per share.

How many Disc Medicine (IRON) shares did Rahul Khara sell in total?

Across the reported transactions, Rahul Khara sold 2,500 shares of Disc Medicine common stock. These sales were split across two days and matched the 2,500 shares acquired through option exercises at an exercise price of $14.69 per share.